Royalty Pharma Q1 adjusted EBITDA climbs 21% to $889 million; portfolio receipts rise 10% to $925 million

Royalty pharma plc

Royalty pharma plc

RPRX

0.00
  • Royalty Pharma reported first-quarter results with Portfolio Receipts rising 10% to $925 million, while Royalty Receipts climbed 13% to $887 million.
  • Net cash provided by operating activities increased 20% to $718 million; adjusted EBITDA rose 21% to $889 million.
  • Announced up to $1.25 billion of new royalty transactions, with first-quarter Capital Deployment totaling $528 million.
  • Raised full-year 2026 Portfolio Receipts guidance to $3.33 billion-$3.45 billion, from $3.28 billion-$3.43 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royalty Pharma plc published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.